Literature DB >> 15824156

Detection of alkaline sphingomyelinase activity in human stool: proposed role as a new diagnostic and prognostic marker of colorectal cancer.

Luisa Di Marzio1, Alfredo Di Leo, Benedetta Cinque, Donatella Fanini, Alessio Agnifili, Pasquale Berloco, Michele Linsalata, Dionigi Lorusso, Michele Barone, Claudio De Simone, Maria Grazia Cifone.   

Abstract

OBJECTIVES: Intestinal alkaline sphingomyelinase, by exerting a major role in dietary sphingomyelin digestion, is responsible for the generation of messengers able to trigger the rapid turnover and apoptosis in intestinal epithelial cells. Markedly reduced mucosal alkaline sphingomyelinase activity has been associated with human colorectal neoplasms. The aim of this study was to analyze the alkaline sphingomyelinase activity in feces from healthy subjects and colorectal adenocarcinoma patients and to correlate it with the enzyme activity in intestinal tissues.
MATERIALS AND METHODS: The enzyme activity was measured both in the intestinal samples from 12 healthy controls and 51 patients with colorectal adenocarcinoma (tumoral and paratumoral tissue) and in the fecal samples of 34 healthy subjects and 29 patients with adenocarcinoma. The relation between sphingomyelinase activity and Dukes' stage, cell differentiation degree, age, and gender was also analyzed.
RESULTS: Alkaline sphingomyelinase was significantly decreased (P < 0.001; mean reduction >90%) in tumoral intestinal mucosa of patients compared with controls independently of Dukes' stage and tumor differentiation grade. Interestingly, the enzyme activity in histologically normal paratumoral tissues was statistically lower than control samples (P < 0.001). As occurs in neoplastic tissues, a relevant mean reduction (P < 0.0001; almost 90%) of alkaline sphingomyelinase was revealed in stool samples from tumor patients when compared with controls.
CONCLUSION: These findings may have implications for cancer biology and perhaps also for the design of clinical test, thus suggesting that the fecal sphingomyelinase activity could really reflect the human intestinal mucosa enzyme level and could represent a new marker for human colorectal adenocarcinoma, mainly taking into account its early appearance in intestinal neoplasms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824156     DOI: 10.1158/1055-9965.EPI-04-0434

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  14 in total

Review 1.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

2.  Fecal metabolomics: assay performance and association with colorectal cancer.

Authors:  James J Goedert; Joshua N Sampson; Steven C Moore; Qian Xiao; Xiaoqin Xiong; Richard B Hayes; Jiyoung Ahn; Jianxin Shi; Rashmi Sinha
Journal:  Carcinogenesis       Date:  2014-07-18       Impact factor: 4.944

3.  Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity.

Authors:  Jun Wu; Ake Nilsson; Bo A G Jönsson; Hanna Stenstad; William Agace; Yajun Cheng; Rui-Dong Duan
Journal:  Biochem J       Date:  2006-02-15       Impact factor: 3.857

Review 4.  Roles of cPLA2alpha and arachidonic acid in cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Biochim Biophys Acta       Date:  2006-09-15

5.  Generating ceramide from sphingomyelin by alkaline sphingomyelinase in the gut enhances sphingomyelin-induced inhibition of cholesterol uptake in Caco-2 cells.

Authors:  Dan Feng; Lena Ohlsson; Wenhua Ling; Ake Nilsson; Rui-Dong Duan
Journal:  Dig Dis Sci       Date:  2010-12       Impact factor: 3.199

Review 6.  Sphingolipids in spinal cord injury.

Authors:  Zachary B Jones; Yi Ren
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-08-05

7.  VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation.

Authors:  I Soo; K L Madsen; Q Tejpar; B C Sydora; R Sherbaniuk; B Cinque; L Di Marzio; M Grazia Cifone; C Desimone; R N Fedorak
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

8.  Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.

Authors:  Caroline B Appleyard; Myrella L Cruz; Angel A Isidro; Janelle C Arthur; Christian Jobin; Claudio De Simone
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-09-08       Impact factor: 4.052

9.  A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface.

Authors:  Xiaoxiao Li; James LeBlanc; Allison Truong; Ravi Vuthoori; Sharon S Chen; Jonathan L Lustgarten; Bennett Roth; Jeff Allard; Andrew Ippoliti; Laura L Presley; James Borneman; William L Bigbee; Vanathi Gopalakrishnan; Thomas G Graeber; David Elashoff; Jonathan Braun; Lee Goodglick
Journal:  PLoS One       Date:  2011-11-21       Impact factor: 3.240

10.  Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions.

Authors:  Itzhak Avital; Russell C Langan; Thomas A Summers; Scott R Steele; Scott A Waldman; Vadim Backman; Judy Yee; Aviram Nissan; Patrick Young; Craig Womeldorph; Paul Mancusco; Renee Mueller; Khristian Noto; Warren Grundfest; Anton J Bilchik; Mladjan Protic; Martin Daumer; John Eberhardt; Yan Gao Man; Björn Ldm Brücher; Alexander Stojadinovic
Journal:  J Cancer       Date:  2013-03-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.